Navigation Links
Late-breaking observational data show patients with type 2 diabetes taking JANUVIA® (sitagliptin) and metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea and metformin
Date:6/14/2014

WHITEHOUSE STATION, N.J., June 14, 2014 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. In this study, patients treated with a combination of JANUVIA and metformin initiated insulin therapy at a slower rate during the period of observation than patients treated with a combination of sulfonylurea and metformin.

"Type 2 diabetes is a progressive disease, so that over time many patients need to add insulin to their treatment regimens to maintain blood sugar control," said Peter Stein, M.D., vice president, Clinical Research for diabetes and endocrinology, Merck Research Laboratories. "This study provides insight about different oral treatment regimens and their possible effect on initiation of insulin under real-world conditions. Real-world research is an important complement to clinical trials as we seek to improve patient health outcomes."

JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA. JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.

Results from "Assessing time to insulin use among type 2 diabetes patients treated with sitagliptin or sulfonylurea plus metformin dual therapy"
'/>"/>

Contact: Pam Eisele
267-305-3558

Kim Hamilton
908-423-6831

Justin Holko
908-423-5088

Merck
Source:Eurekalert


Page: 1 2 3 4 5

Related medicine news :

1. Hot Line IV: Late-breaking trials on heart failure and acute coronary syndrome
2. A large, observational study of common gout treatment allopurinol shows less than half of patients reach recommended treatment goal
3. New post-hoc analysis shows patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia (Sitagliptin) compared to placebo
4. BRCA test results affect patients breast cancer surgery plans
5. Genotyping can predict disease outcomes in rheumatoid arthritis patients
6. Ipilimumab in advanced melanoma: added benefit for non-pretreated patients not proven
7. Recreational football can treat hypertensive and type 2 diabetes patients
8. Low cholesterol linked with worse survival in patients with kidney cancer
9. One-third of psoriatic arthritis patients are not receiving optimal dosing of adalimumab
10. Higher disease activity scores in obese RA patients
11. First clinical diabetes registry to provide seamless view of patients across specialties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... Guinness International Champions Cup Finals tickets at the Sun ... 2014 Guinness International Champions Cup is now underway. Residents and ... to be able to watch the Guinness International Champions Cup ... The eight teams competing in the tournament have been split ...
(Date:7/31/2014)... Daily Gossip indicates in its "Neuropathy Miracle" review ... problem. However, this is not a solution. , The ... Peter Bansby, who decided to reveal his method with ... world find a unique way of overcoming their health ... and cons from a full Neuropathy Miracle review, simply ...
(Date:7/31/2014)... Andrie, Inc. V. Dept. of Treasury, Mich. S. ... has made the determination that a purchaser of tangible goods ... was unable to prove during an audit that sales ... Court of Appeals decision on whether a purchaser bears the ... purchases from Michigan sellers. The Court states “in order to ...
(Date:7/31/2014)... Washington, New York (PRWEB) July 31, 2014 ... represents whistleblowers in qui tam cases, comments that whistleblowers ... an end to illegal employer activities that may cause ... recognizes that today is National Whistleblower Appreciation Day. , ... National Whistleblower Center , the Senate declared "National Whistleblower ...
(Date:7/31/2014)... Stamford, CT (PRWEB) July 31, 2014 You’re ... friends. So why have you suddenly developed chills and fever, ... exhaustion? If you suspect a flu-like illness, it could actually ... , Your risk of developing Lyme is greater than ... about 30,000 new cases occurred in the U.S. annually. But ...
Breaking Medicine News(10 mins):Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 2Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 4Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3
... always ideal for many with low risk disease, researchers ... patients with prostate cancer that has a low risk ... may be a suitable treatment option, according to a ... (or whether) to treat localized prostate cancer is controversial ...
... ... MD is now performing a new procedure at Baptist Medical Center in Jackson, Miss. ... referred to as a myomectomy, or fibroidectomy. , ... Jackson, MS (Vocus) June 18, 2010 -- Baptist Medical ...
... Poor kids in bilingual families need extra support, study ... children in poor families are at increased risk for ... summer holidays, according to the American Speech-Language-Hearing Association. , ... the summer, says the ASHA, which offers the following ...
... Rome, Italy, Friday 18 June 2010: There is significant ... terms of access to biological treatments for rheumatoid arthritis ... four continents presented today at EULAR 2010, the Annual ... Italy. Furthermore, findings from a separate study show that ...
... , ... In today’s back to school environment, many ... have seen on T.V. or the Internet to inquire about returning ... realize is that their work and military experience, training certificates, licenses ...
... consumption dropped, study found , FRIDAY, June 18 (HealthDay ... may reduce consumption and help lower levels of obesity ... suggests. , Researchers examined what happened during a time ... in Boston increased the price of regular soft drinks ...
Cached Medicine News:Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:GYN Oncologist Uses da Vinci Surgical Robot to Preserve Fertility 2Health News:Country economy is a stronger predictor of therapy initiation 2Health News:College Equalizer Takes College Counseling Beyond the Status Quo to Help Adult Learners Find the Best School 2Health News:College Equalizer Takes College Counseling Beyond the Status Quo to Help Adult Learners Find the Best School 3Health News:People May Skip Soft Drinks Rather Than Pay More 2
(Date:7/31/2014)... Hovione today announced that its API plant in ... pre-approval inspection by the US Food and Drug Administration (FDA). ... Safety Officer, Ms. Britanny Terhar , lasted 5 days ... concluded on the 25 th . The inspection confirmed the ... Good Manufacturing Practices (GMP) and no Form 483 observations were ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... in New York results of AFF008, ... Parkinson,s disease. PD01A is the first therapy against the protein ... The Michael J. Fox Foundation for Parkinson,s Research ... and presented at the press conference on the impact a ...
(Date:7/31/2014)... 2014 Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics ... a conference call on Thursday, August 14, 2014, at 4:30 ... ended June 30, 2014. Financial results will be issued in ... Chairman, President and CEO James LaFrance will host ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. Eastern ...
Breaking Medicine Technology:Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... Life Technologies Corporation (NASDAQ: LIFE ) ... with GlaxoSmithKline Biologicals S.A. (GSK) to develop a diagnostic ... GSK candidate cancer immunotherapy. Specifically, Life will develop a ... candidate designed to identify patients likely to benefit from ...
... (Cayman) Inc. (NYSE: WX ), a leading ... operations in China and the United States, today announced ... quarter of 2011 after the New York Stock Exchange ... Friday morning, November 11, 2011 Shanghai time). The earnings ...
Cached Medicine Technology:Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 2Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 3Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics 4WuXi PharmaTech Schedules Third-Quarter 2011 Earnings Release 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: